ArticleNano research2022
Sensitively detecting antigen of SARS-CoV-2 by NIR-II fluorescent nanoparticles.
Article in Nano research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 47 citations in OpenAlex.
- A New Sensitive Sensor Test for Capturing and Evaluating Bacteria and Viruses in Airborne Aerosols.Sensors (Basel, Switzerland) · 2025Article
- Simultaneously ultrasensitive and differential detection of SARS-CoV-2, adenovirus and influenza a virus using multiplex fluorescence lateral flow immunoassay.Frontiers in immunology · 2025Article
- Rapid diagnosis of different cardiovascular disease events from early released cardiac biomarkers, cTnI, BNP, and CRP, by biosensor technology.Frontiers in cardiovascular medicine · 2025Article
- Fluorescence-enhanced dual signal lateral flow immunoassay for flexible and ultrasensitive detection of monkeypox virus.Journal of nanobiotechnology · 2023Article
- NIR-II fluorescent AgMikrochimica acta · 2023Article
- Two-Dimensional (2D) materials in the detection of SARS-CoV-2.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023Article
- Article
- Aggregation-Induced Emission (AIE), Life and Health.ACS nano · 2023Review
- Multifunctional N,S-doped and methionine functionalized carbon dots for on-off-on FeNano research · 2023Article
- Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an efficient way to prevent the spread of coronavirus disease 2019 (COVID-19). Detecting SARS-CoV-2 antigen can be rapid and convenient, but it is still challenging to develop highly sensitive methods for effective diagnosis. Herein, a lateral flow assay (LFA) based on fluorescent nanoparticles emitting in the second near-infrared (NIR-II) window is developed for sensitive detection of SARS-CoV-2 antigen. Benefiting from the NIR-II fluorescence with high penetration and low autofluorescence, such NIR-II based LFA allows enhanced signal-to-background ratio, and the limit of detection is down to 0.01 ng·mL Electronic Supplementary Material: Supplementary material (the operation procedure and cost of the materials needed of NIR-II lateral flow assays, the dynamic light scattering spectrum of the NIR-II nanoparticles, the components and testing principle, optimization of main parameters pertaining to the LFA performance, the colloidal gold LFA strip, the fluorescence intensity distribution curves and the T/C values of the strips for clinical samples by NIR-II LFA, and results of clinical swab samples detected by colloidal gold LFA) is available in the online version of this article at 10.1007/s12274-022-4351-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.